Summary

The global continuous glucose monitoring systems (CGMS) market was valued at approximately USD 6,626.6 million in 2021 and is expected to grow to USD 31,708.2 million by 2032, with a CAGR of 17.0% from 2022 to 2032. Continuous glucose monitoring systems (CGMs) are pivotal medical devices that provide real-time glucose level monitoring for patients, enabling better management of diabetes. These systems consist of sensors, transmitters, and display devices, offering continuous data to patients and healthcare providers. The burgeoning demand for CGMs is driven by the rising incidence of diabetes and the increasing preference for home care applications.
The market dynamics are influenced by the growing innovations in medical devices for CGM manufacturing, creating numerous opportunities. Notably, developments such as the world's first multi-sensor non-invasive CGM by GlucoRx and Cardiff University in 2022 exemplify the technological advancements propelling market growth. Additionally, the increasing geriatric population and prevalence of diabetes further fuel market expansion. However, high costs and regulatory challenges in developing regions pose constraints. Yet, the anticipated rise in healthcare investments and advancements in R&D in emerging economies are projected to offer significant growth opportunities.
Regionally, North America dominated the market in 2021, attributed to the presence of key players, high prevalence of diabetes, and well-established healthcare infrastructure. The Asia-Pacific region is expected to witness the highest growth rate due to the increasing geriatric population, advancements in healthcare infrastructure, and rising awareness about CGMs.
Major market players included in this report are:
• A. Menarini Diagnostics S.r.l
• Abbott Laboratories
• DexCom, Inc.
• F. Hoffman-La Roche Ltd
• GlySens Incorporated
• Johnson & Johnson
• Medtronic plc
• Novo Nordisk A/S
• Senseonics
• Ypsomed AG
The detailed segments and sub-segments of the market are explained below:
By Component:
• Sensors
• Transmitters & Receivers
By Demography:
• Child Population (≤14 years)
• Adult Population (>14 years)
By End User:
• Hospitals & Clinics
• Home Healthcare
• Others
Common content for ‘Report Description’
By Region: North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global Continuous Glucose Monitoring Systems Market Executive Summary
1.1. Global Continuous Glucose Monitoring Systems Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Component
1.3.2. By Demography
1.3.3. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Continuous Glucose Monitoring Systems Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Continuous Glucose Monitoring Systems Market Dynamics
3.1. Market Drivers
3.1.1. Growth & Innovations in Medical Device Industry
3.1.2. Rise in Prevalence of Diabetes
3.1.3. Increase in Geriatric Population
3.2. Market Challenges
3.2.1. High Costs of CGMs
3.2.2. Regulatory and Reimbursement Issues
3.3. Market Opportunities
3.3.1. Advancements in R&D
3.3.2. Growing Demand in Emerging Markets
3.3.3. Increasing Awareness and Adoption

Chapter 4. Global Continuous Glucose Monitoring Systems Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Continuous Glucose Monitoring Systems Market Size & Forecasts by Component 2022-2032
5.1. Segment Dashboard
5.2. Global Continuous Glucose Monitoring Systems Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Sensors
5.2.2. Transmitters & Receivers

Chapter 6. Global Continuous Glucose Monitoring Systems Market Size & Forecasts by Demography 2022-2032
6.1. Segment Dashboard
6.2. Global Continuous Glucose Monitoring Systems Market: Demography Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Child Population (≤14 years)
6.2.2. Adult Population (>14 years)

Chapter 7. Global Continuous Glucose Monitoring Systems Market Size & Forecasts by End User 2022-2032
7.1. Segment Dashboard
7.2. Global Continuous Glucose Monitoring Systems Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Hospitals & Clinics
7.2.2. Home Healthcare
7.2.3. Others

Chapter 8. Global Continuous Glucose Monitoring Systems Market Size & Forecasts by Region 2022-2032
8.1. North America Continuous Glucose Monitoring Systems Market
8.1.1. U.S. Continuous Glucose Monitoring Systems Market
8.1.1.1. Component breakdown size & forecasts, 2022-2032
8.1.1.2. Demography breakdown size & forecasts, 2022-2032
8.1.1.3. End User breakdown size & forecasts, 2022-2032
8.1.2. Canada Continuous Glucose Monitoring Systems Market
8.2. Europe Continuous Glucose Monitoring Systems Market
8.2.1. U.K. Continuous Glucose Monitoring Systems Market
8.2.2. Germany Continuous Glucose Monitoring Systems Market
8.2.3. France Continuous Glucose Monitoring Systems Market
8.2.4. Spain Continuous Glucose Monitoring Systems Market
8.2.5. Italy Continuous Glucose Monitoring Systems Market
8.2.6. Rest of Europe Continuous Glucose Monitoring Systems Market
8.3. Asia-Pacific Continuous Glucose Monitoring Systems Market
8.3.1. China Continuous Glucose Monitoring Systems Market
8.3.2. India Continuous Glucose Monitoring Systems Market
8.3.3. Japan Continuous Glucose Monitoring Systems Market
8.3.4. Australia Continuous Glucose Monitoring Systems Market
8.3.5. South Korea Continuous Glucose Monitoring Systems Market
8.3.6. Rest of Asia Pacific Continuous Glucose Monitoring Systems Market
8.4. Latin America Continuous Glucose Monitoring Systems Market
8.4.1. Brazil Continuous Glucose Monitoring Systems Market
8.4.2. Mexico Continuous Glucose Monitoring Systems Market
8.4.3. Rest of Latin America Continuous Glucose Monitoring Systems Market
8.5. Middle East & Africa Continuous Glucose Monitoring Systems Market
8.5.1. Saudi Arabia Continuous Glucose Monitoring Systems Market
8.5.2. South Africa Continuous Glucose Monitoring Systems Market
8.5.3. Rest of Middle East & Africa Continuous Glucose Monitoring Systems Market

Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. A. Menarini Diagnostics S.r.l
9.1.2. Abbott Laboratories
9.1.3. DexCom, Inc.
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. F. Hoffman-La Roche Ltd
9.3.2. GlySens Incorporated
9.3.3. Johnson & Johnson
9.3.4. Medtronic plc
9.3.5. Novo Nordisk A/S
9.3.6. Senseonics
9.3.7. Ypsomed AG

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes